You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
Many sponsors of violate the spirit of the law requiring reports on studies by giving substandard effort in their trial registrations and reported results. They face no penalties for shoddy work, which often delays public disclosure. Science found that faulty results and trial registrations—which have the effect of temporarily keeping data secret—are rampant. And although most big pharma companies generally follow the letter of the law, they often "game the system," experts say, by failing to register many of the trials they use to gain federal approval for new drugs.
